Founded in 2016, by Kavli INsD's Professor Achillefs Kapanidis, ONI is now a leading and rapidly growing biotech redefining the boundaries of scientific discovery with super-resolution microscopy. The CEO and co-founder of the company, Bo Jing, is also a former member of the Kapanidis Group. Find out more.


Founded by Kavli INsD Professors Justin Benesch and Phillip Kukura, Refeyn was spun out in 2018 with the goal to make mass photometry available to the scientific community. The opportunity around our unique technology has attracted a passionate team of people who collectively have spent decades in the development and commercialization of microscopes and other analytical instrumentation. Find out more.

OMass Therapeutics

Co-Founded by Kavli INsD Director, Professor Dame Carol Robinson with Dr Jonathan Hopper, OMass Therapeutics is an Oxford University spin-out backed by Syncona and Oxford Science Enterprises that is using novel biochemistry techniques, native mass spectrometry and custom chemistry to deliver novel medicines against highly validated but inadequately drugged targets, with a focus on immunological and rare diseases. Find out more.

Circadian Therapeutics logo

Circadian Therapeutics

Circadian Therapeutics was founded in September 2016 by Kavli INsD Professors Aarti Jagannath and Russell Foster with the aim to deliver benefit and value for all its stakeholders; patients, healthcare providers and investors. The world-leading science generated by its academic founders is the foundation for the development of therapeutic products based on the understanding of the molecular control of circadian rhythms. With an experienced leadership team and a track-record of building operational capabilities and delivering shareholder value, the Company will develop therapeutics targeting serious diseases associated with circadian rhythm disruption. Find out more.